1. Home
  2. STAA vs NVAX Comparison

STAA vs NVAX Comparison

Compare STAA & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo STAAR Surgical Company

STAA

STAAR Surgical Company

HOLD

Current Price

$27.68

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Logo Novavax Inc.

NVAX

Novavax Inc.

HOLD

Current Price

$9.35

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STAA
NVAX
Founded
1982
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Ophthalmic Goods
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.5B
IPO Year
1995
1996

Fundamental Metrics

Financial Performance
Metric
STAA
NVAX
Price
$27.68
$9.35
Analyst Decision
Buy
Hold
Analyst Count
9
9
Target Price
$22.81
$11.33
AVG Volume (30 Days)
634.0K
4.1M
Earning Date
05-12-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
309.76
EPS
0.10
N/A
Revenue
$239,442,000.00
$1,123,479,000.00
Revenue This Year
$30.82
N/A
Revenue Next Year
$8.41
N/A
P/E Ratio
$279.70
N/A
Revenue Growth
N/A
64.69
52 Week Low
$15.59
$6.20
52 Week High
$35.87
$11.85

Technical Indicators

Market Signals
Indicator
STAA
NVAX
Relative Strength Index (RSI) 44.97 50.60
Support Level $23.75 $8.89
Resistance Level $31.17 $10.10
Average True Range (ATR) 1.35 0.51
MACD -0.17 0.03
Stochastic Oscillator 33.70 57.84

Price Performance

Historical Comparison
STAA
NVAX

About STAA STAAR Surgical Company

Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company offers two types of products: Implantable Collamer lenses (ICL), which are used in refractive surgery. The company generates almost all of its revenue from the sale of its ICL products. Geographically, the company generates key revenue from Foreign sales.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

Share on Social Networks: